Abstract PO3-04-05: Efficacy and safety of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive or HER2-low expressing, metastatic breast cancer: a single-arm phase II study
Authors: Fei Qu, Wei Li, Yongmei Yin, Qian Liu
Published: 2024-05-02
DOI:
10.1158/1538-7445.sabcs23-po3-04-05
Source:
Full article
Abstract
Abstract